Key Highlights
- Net loss was USD 5.8 million, or USD 0.40 per share, versus USD 0.34 estimated.
- Research and development expense rose to USD 5.4 million from USD 3.3 million.
- Cash was USD 5.9 million at September 30, 2026.
- The at-the-market program raised USD 9.3 million in nine months.
Research Spending Drives a Wider Loss
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) reported a third-quarter net loss of USD 5,813,533, or USD 0.40 per share, versus USD 3,711,269, or USD 0.27, and compared with an estimated loss of USD 0.34 per share. Research and Development expense rose to USD 5,447,804 from USD 3,267,140, while general and administrative expense eased to USD 412,695 from USD 466,926.
Total operating expenses were USD 5,860,499 versus USD 3,734,066, and interest income was USD 46,966 versus USD 22,797. The company has not generated revenue.
The filing states that net losses were approximately USD 19.4 million for 2025 and USD 17.4 million for 2024, and that the company expects to continue incurring significant expenses and increased operating losses.
Per-share loss for the nine months of USD 1.05 compares with USD 0.76 a year earlier, and the quarter's USD 0.40 compares with USD 0.27, as the weighted share count rose to 14.7 million.
Nine-Month Results
For the nine months, net loss was USD 15,419,345, or USD 1.05 per share, versus USD 10,204,689, or USD 0.76. Research and development was USD 14,214,082 versus USD 8,954,765, general and administrative was USD 1,393,816 versus USD 1,317,366, and total operating expenses were USD 15,607,898 versus USD 10,272,131. Interest income was USD 188,553 versus USD 67,442.
Weighted average shares were 14,678,208 in the quarter versus 13,641,384.
Weighted average shares for the nine months were 14,640,432 versus 13,396,362. Accounts Payable and accrued interest rose to USD 6,903,175 from USD 4,874,489 at December 31, 2025, and deferred compensation to a related party was USD 673,819.
Flamingo-01 and Funding
The company is a "clinical-stage biopharmaceutical company focused on our Phase III clinical trial, Flamingo-01", which evaluates the GP2 immunotherapy for preventing breast cancer recurrences in HER2/neu positive patients. It says it is expanding the trial into Europe with plans for up to 150 sites globally.
Cash was USD 5,898,582 versus USD 6,178,021 at December 31, 2025. Net cash used in Operating Activities was USD 9,620,015 versus USD 6,738,796, funded by USD 9,340,576 of net proceeds from sales of common stock through its at-the-market program. Total liabilities were USD 7,645,466, and total stockholders' Equity was a Deficit of USD 1,746,884.
The GP2 peptide is described as a nine amino acid transmembrane peptide of the HER2/neu protein, which the filing says is expressed in 75% of breast cancers at low, intermediate and high levels.
The net decrease in cash for the nine months was USD 279,439 versus USD 285,012, with cash at the end of the prior-year period at USD 3,806,978.
Items to Follow
Reference points include trial site expansion in Europe, research spending relative to the cash balance, further use of the at-the-market program and the stockholders' deficit.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...